Profile of nintedanib in the treatment of solid tumors: the evidence to date

Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Niranjan, Schwarz, Roderich E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677757/
https://www.ncbi.nlm.nih.gov/pubmed/26677336
http://dx.doi.org/10.2147/OTT.S78805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4677757/
https://www.ncbi.nlm.nih.gov/pubmed/26677336
http://dx.doi.org/10.2147/OTT.S78805

Ejemplares similares